A 55-year-old man with hypertension is on amlodipine 10 mg/day. His blood pressure remains uncontrolled. His physician adds telmisartan. This combination is preferred over the ACE inhibitor-CCB combination in elderly patients primarily because telmisartan:
- A Has a longer half-life than amlodipine, preventing end-of-dose rebound hypertension
- B Prevents ACE inhibitor-induced cough and angioedema that commonly limit combination therapy
- C Is a partial agonist at PPAR-gamma receptors, providing additional metabolic benefits beyond blood pressure control ✓
- D Blocks aldosterone synthesis directly, providing superior potassium-sparing effects
Explanation
Telmisartan is unique among ARBs in being a partial agonist at PPAR-gamma receptors, which improves insulin sensitivity and lipid profiles — providing metabolic benefits beyond blood pressure control that are particularly relevant in patients with metabolic syndrome or diabetes. This distinguishes it from other ARBs. Telmisartan also has the longest half-life among ARBs (24 hours), but this alone does not explain its preference over ACE inhibitors. The CCB-ARB combination lacks the cough/angioedema concern of ACE inhibitors, but that is a general ARB class property.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.